rh-ES and Chemotherapy in Advanced Gastrointestinal Cancer in China: A Meta-analysis

Background: The purpose of this study was to evaluate the efficacy and safety of recombinant human endostatin (rh-ES) combined with chemotherapy in advanced gastrointestinal tumors in China. Methods: A literature search was performed in PubMed, Medline, Springer, Elsevier Science Direct, Weipu, Wanfang, and China National Knowledge Infrastructure (CNKI), with the last report through September 2019. The included research was scored using a modified Jadad scale, and a meta-analysis was performed using RevMan 5.3 software. Results: Twenty articles including 905 participants (experimental group [rh-ES combined with chemotherapy] 459; control group [chemotherapy alone] 446) were considered. The total effective rate for the experimental group in advanced gastrointestinal tumors was higher than that of the control group (P<0.05). No significant difference in adverse reactions was seen between the two groups (P<0.05). Conclusions: The short-term efficacy of rh-ES combined with chemotherapy for advanced gastrointestinal tumors was better, with fewer adverse reactions.

Automated summary

This study evaluated the efficacy and safety of recombinant human endostatin combined with chemotherapy in advanced gastrointestinal tumors in China. The results showed that the short-term efficacy of rh-ES combined with chemotherapy was better, with fewer adverse reactions.